May 26, 2025 a 01:01 pm
CAH: Fundamental Ratio Analysis - Cardinal Health, Inc.
Cardinal Health, Inc. is poised within the integrated healthcare services and products industry with diversified operations globally. Their strategic segments continue to foster the company's growth across pharmaceutical and medical product lines. The upcoming fiscal year looks promising with a stable outlook based on recent fundamental analysis scores.
Fundamental Rating
The fundamental analysis gives Cardinal Health a B- rating, indicating stable performance with room for improvement in some areas.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 5 | |
| Return On Equity | 1 | |
| Return On Assets | 4 | |
| Debt To Equity | 1 | |
| Price To Earnings | 2 | |
| Price To Book | 1 |
Historical Rating
Recent scores highlight an improvement in Cardinal Health's overall rating from past to present, preparing for potential growth.
| Date | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-05-23 | 2 | 5 | 1 | 4 | 1 | 2 | 1 |
| Past | 0 | 5 | 1 | 4 | 1 | 2 | 1 |
Analyst Price Targets
The analyst consensus suggests a uniform price target for Cardinal Health, indicative of market stability and potential value recognition.
| High | Low | Median | Consensus |
|---|---|---|---|
| 148 | 148 | 148 | 148 |
Analyst Sentiment
Analyst sentiment on Cardinal Health skews positively, with a clear lean towards 'Buy' recommendations signaling potential upward mobility.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 15 | |
| Hold | 15 | |
| Sell | 0 | |
| Strong Sell | 0 |
Conclusion
Cardinal Health, Inc. emerges as a stable entity with consistent analyst backing and a robust strategic footprint across global markets. While current scores reveal areas for financial metric improvement, the company’s established market presence and operational efficiency provide a buffer against potential risks. The evaluations indicate a balanced outlook, favoring growth with certain strategic enhancements. Investor confidence remains bolstered by achieved price targets and optimistic analyst sentiments.